company background image
DP81 logo

Diffusion Pharmaceuticals BST:DP81 Stock Report

Last Price

€5.70

Market Cap

€12.5m

7D

0%

1Y

-53.3%

Updated

13 Feb, 2023

Data

Company Financials +

Diffusion Pharmaceuticals Inc.

BST:DP81 Stock Report

Market Cap: €12.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DP81 Stock Overview

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. More details

DP81 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Diffusion Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Diffusion Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.70
52 Week HighUS$11.87
52 Week LowUS$5.25
Beta1.81
1 Month Change0%
3 Month Changen/a
1 Year Change-53.28%
3 Year Change-65.66%
5 Year Change-98.49%
Change since IPO-99.38%

Recent News & Updates

Recent updates

Shareholder Returns

DP81DE BiotechsDE Market
7D0%-1.7%-2.8%
1Y-53.3%-13.5%10.0%

Return vs Industry: DP81 underperformed the German Biotechs industry which returned 3.3% over the past year.

Return vs Market: DP81 underperformed the German Market which returned -9.8% over the past year.

Price Volatility

Is DP81's price volatile compared to industry and market?
DP81 volatility
DP81 Average Weekly Movementn/a
Biotechs Industry Average Movement8.6%
Market Average Movement5.5%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.8%

Stable Share Price: DP81 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DP81's volatility change over the past year.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

About the Company

FoundedEmployeesCEOWebsite
200116Bob Cobuzziwww.diffusionpharma.com

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Diffusion Pharmaceuticals Inc. Fundamentals Summary

How do Diffusion Pharmaceuticals's earnings and revenue compare to its market cap?
DP81 fundamental statistics
Market cap€12.52m
Earnings (TTM)-€13.98m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DP81 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.99m
Earnings-US$14.99m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.35
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DP81 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/02/13 22:03
End of Day Share Price 2022/11/16 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diffusion Pharmaceuticals Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
David BautzZacks Investment Research Inc.
David BautzZacks Small-Cap Research